The surgeon general wants the U.S. to know alcohol causes cancer. Plenty stands in his way
The outgoing surgeon general will have to rely on Congress and the next administration to add warnings about cancer risks to alcohol labels.
Related Articles
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials – PubMed
Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a clinical trial, we…
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell…
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes – PubMed
Of patients with NDMM enrolled in the Connect MM Registry, 40% are ineligible for RCTs. This study provides insight into potential modifications of standard eligibility…
Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance
PURPOSE Molecular tumor boards (MTBs) provide interventions that assist the patient’s primary oncologist’s interpretation and application of precision oncology and avoid clinical and financial toxicities…
Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One
Precision medicine is a term describing strategies to promote health and prevent and treat disease based on an individual’s genetic, molecular, and lifestyle characteristics. Oncology…
Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems.
6539 Background: Precision medicine (PM) molecular panel (MP) testing report actionable findings with associated targeted therapies (including immunotherapies). However, these actionable findings “reported actionability” by…
Successful automated normalization of cancer outcomes for half a million patients across four disparate health systems.
e18763 Background: The lack of interoperability among different electronic medical record (EMR) systems remains a challenge to fulfilling the promises of precision oncology. Typically, cancer…
Role of Community-Based Genomics Programs
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family…
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board
Purpose Precision oncology develops and implements evidence-based personalized therapies that are based on specific genetic targets within each tumor. However, a major challenge that remains…
Feb 5-7 Program: 400-Speaker & 12-Track @PMWC in California
PMWC Silicon Valley’s Program. 400+ talks run from 9-5 over 3 days & cover a wide range of precision medicine topics, click for more details
